Navigation Links
Shield Therapeutics Selects OpenClinica Enterprise
Date:1/5/2013

Waltham, MA & Wollerau, Switzerland (PRWEB) January 04, 2013

OpenClinica, LLC and Shield Therapeutics announces that Shield Therapeutics has selected the OpenClinica Enterprise software for its clinical data management needs related to the company’s clinical trials. Shield Therapeutics develops treatments for unmet medical needs, and is currently running a Phase III program for ST10, a novel orally delivered ferric iron-based therapy to treat iron deficiency.

“The OpenClinica system should enable us to collect data from participating clinical trial sites faster and with a higher level of quality,” said Carl Sterritt, Shield’s CEO. “We also hope that an added benefit of the OpenClinica Enterprise Edition will be facilitation of our regulatory compliance efforts.”

OpenClinica offers a unique and flexible model for its clinical trial software. “As commercial open source software, OpenClinica allows organizations like Shield Therapeutics to benefit from powerful, widely adopted, open source technology, while obtaining a fully supported implementation and a robust regulatory infrastructure, said Cal Collins, CEO at OpenClinica, LLC. “We are excited to welcome Shield Therapeutics to our rapidly growing community and Enterprise customer base.”

About Shield Therapeutics®

Shield Therapeutics is a Swiss-based specialty pharmaceutical company focused on the development and commercialization of novel mineral-based therapies to treat diseases with significant unmet medical need. The company was founded in 2008 and is currently undertaking a multi-national pivotal Phase III program for its lead asset, ST10, for the treatment of iron deficiency anaemia (IDA) associated with inflammatory bowel disease (IBD). For more information see http://www.shieldtx.com.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Molderizer and Safe Shield Get a Price Decrease; My Cleaning Products Says Its the Company's Christmas Treat
2. Mold Linked With Fatal Asthma and Allergy Attacks; Dr Mold Network Suggests Use of Molderizer and Safe Shield for Safer Mold Treatment
3. Christmas Special: My Cleaning Products Celebrates Holiday With a Molderizer and Safe Shield Markdown for its Clients
4. Pinnaclife Animal Health Features Seal N Heal Wound Shield in New Veterinary Dermatologist Tested and Approved Product Line!
5. Not your average heat shield
6. Agendia Signs Contract with Blue Shield of California
7. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
8. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
9. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
10. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
11. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
(Date:7/25/2015)... ... ... Technology leader Anton Paar offers the Abbemat T-Check ... of the measuring prism. This is required to achieve the most precise refractive ... requirements. It is likely that no refractometer manufacturers on the market can traceably ...
(Date:7/24/2015)... DIEGO , July 24, 2015 Orexigen ... and financial results for the second quarter 2015 on ... announcement, Orexigen will provide a business update and discuss ... call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific ... by phone by calling (800) 447-0521 (domestic) or (847) ...
(Date:7/23/2015)... , July 23, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... financial results for the second quarter 2015 on Thursday, August ... call and webcast on that day at 5:00 pm ET ... a business update. The call will be hosted by ... , , , LIVE CALL: , , ...
Breaking Biology Technology:Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6It’s T-Time for Refractometers: On-site Temperature Check Now Available 2ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2
... , ... CEO, Matthew Sarad, plans a series of experiments to demonstrate the power of nanotechnology ... ... Mr. Matthew Sarad, has announced plans to attempt to rejuvenate living animals with advanced ...
... HORSHAM, Pa., Sept. 10 Centocor Ortho Biotech Products, L.P. ... U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug ... in combination with docetaxel for the treatment of women with ... Centocor Ortho Biotech is evaluating the FDA,s letter and ...
... , ABBOTT PARK, Ill. and MENLO ... announced today a definitive agreement to acquire the outstanding equity of ... minimally invasive repair of cardiac mitral valves. The acquisition provides ... for structural heart disease, in which physicians use catheter-based devices to ...
Cached Biology Technology:Matthew Sarad to Reverse Aging and Cure Cancer 2Matthew Sarad to Reverse Aging and Cure Cancer 3Matthew Sarad to Reverse Aging and Cure Cancer 4Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 2Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 3Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 4Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 5Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 2Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 3Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 4
(Date:6/25/2015)... 2015  Imagine a tool specifically designed to help ... life. That,s exactly what USANA,s True Health Assessment ... portable health program provides a personalized approached to measuring ... your lifestyle and nutrition. At the ... night, USANA,s THA was honored with the Industry Innovation ...
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... Systems market, over the next six years. It contains ... affect the industry, along with their impact from the ... It also discusses the industry, market, and technology ... expected that the need of concerned authorities to efficiently ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Resources, one of the world,s leading research and advisory ... most of the biomarker-drug success stories are in oncology, ... chronic conditions, and their use in clinical trials of ... report entitled Driving Drug and Diagnostic R&D: ...
... 2013 -- Researchers have identified some of the underlying physics ... a stall in midflight -- unlike conventional fixed wing aircraft, ... The analysis, in which the researchers studied the ... how insects fly and informs the design of small flying ...
... 2013 A bicoastal group of scientists at Sanford-Burnham ... grant from the U.S. Department of the Air Force ... chemicals. The goal of the project is to provide ... a rapid, cost-effective manner. "The current approach to ...
Cached Biology News:Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing 2Sanford-Burnham receives US Air Force grant to perform next-generation toxicity screens 2
... ChipWriter Pro system, 220-240 V, uses floating ... oligonucleotides, carbohydrates, lipids, and other biomolecules onto ... This system can generate high-density arrays with ... or greater than 57,000 spots per membrane ...
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
The SmartSpec printer paper is used to record data generated by the SmartSpec Plus spectrophotometer. Supplied as 5 packs....
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Biology Products: